1. Home
  2. NGNE vs LWAY Comparison

NGNE vs LWAY Comparison

Compare NGNE & LWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$27.00

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

LWAY

Lifeway Foods Inc.

HOLD

Current Price

$27.41

Market Cap

333.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
LWAY
Founded
2003
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Packaged Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
333.6M
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
NGNE
LWAY
Price
$27.00
$27.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
$63.57
$35.00
AVG Volume (30 Days)
138.7K
76.3K
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
0.93
48.33
EPS
N/A
0.89
Revenue
N/A
$103,350,000.00
Revenue This Year
N/A
$16.64
Revenue Next Year
N/A
$17.28
P/E Ratio
N/A
$29.52
Revenue Growth
N/A
N/A
52 Week Low
$11.78
$17.31
52 Week High
$37.27
$34.20

Technical Indicators

Market Signals
Indicator
NGNE
LWAY
Relative Strength Index (RSI) 64.63 78.34
Support Level $19.40 $24.61
Resistance Level $29.05 $28.61
Average True Range (ATR) 1.86 1.02
MACD 0.53 0.34
Stochastic Oscillator 78.73 97.85

Price Performance

Historical Comparison
NGNE
LWAY

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About LWAY Lifeway Foods Inc.

Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir, which is a cultured dairy product. Its product categories are Drinkable Kefir, which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir, and Other dairy. The company manufactures and markets products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through a direct sales force, brokers, and distributors.

Share on Social Networks: